SHANGHAI, July 24,
2022 /PRNewswire/ -- Qiming Venture Partners'
portfolio company InventisBio (SHSE: 688382), a leading company in
innovative drug development, today listed on the Science and
Technology Innovation Board (the "STAR Market") of the Shanghai
Stock Exchange. The issue price is
CNY 18.12 per share, representing a
market cap of CNY 10.419
Qiming Venture Partners invested in InventisBio in September 2020. The successful listing of the
company marks the fourth IPO in Qiming's portfolio in 2022.
InventisBio has become the ninth portfolio company listed on the
InventisBio is a China-based
global biotech company dedicated to the research and development
(R&D) of innovative drugs, with a focus on cancer, metabolic
diseases and other major diseases. The company is co-founded by
several professional experts with international backgrounds.
InventisBio's core R&D team members have an average of more
than 20 years of experience in innovative drug R&D and team
management in multinational pharmaceutical companies.
With strength and rich experience in drug R&D, InventisBio
has independently developed a series of innovative targeted drugs
with patent protection, covering non-small cell lung cancer
(NSCLC), breast cancer, colorectal cancer and other solid tumors,
as well as metabolic diseases such as hyperuricemia and gout.
InventisBio has business cooperation with well-known
pharmaceutical enterprises including Betta Pharma, Pfizer, and
Merck (MSD) among many others. Currently, with three core products
at the clinical trial stage, five projects at the pre-clinical
stage, and three core products entering phase II or phase III
clinical registration trials, the company has been foremost among
those who have made progress in drug R&D in China and even the world.
According to InventisBio, the company is committed to addressing
unmet medical needs, developing innovative drugs with proprietary
rights to be marketed worldwide, and consistently providing
patients with safer, more effective and more affordable treatments.
The successful listing on the STAR Market brings a new opportunity
to InventisBio. The company will accelerate its product
industrialization and commercialization, while continuing to enrich
the product pipeline by advancing more candidate compounds into
global clinical trial phases.
Dr. Kan Chen, Partner of Qiming Venture Partners, said,
"Equipped with rich experience in innovative drug development,
InventisBio's team has profound insights into the industry trends.
The company's product pipeline has made progress to date. Many
projects have entered the clinical stage or late-clinical stage and
demonstrated best-in-class potential. The company's IPO is a new
starting point, and we look forward to InventisBio strengthening
its industrialization and commercialization capability to better
benefit patients with more of its products entering the
late-clinical stage and obtaining approval to be marketed."
About Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a leading
China venture capital firm with
offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San
Francisco Bay Area.
Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4
billion in capital raised. Since our establishment, we have
invested in outstanding companies in the Technology and Consumer
(T&C) and Healthcare industries at the early and growth
Since our debut, we have backed over 480 fast-growing and
innovative companies. Over 180 of our portfolio companies have
achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai
Stock Exchange or Shenzhen Stock Exchange, or through M&A or by
other means. There are also over 70 portfolio companies that have
achieved unicorn status.
Many of our portfolio companies are today's most influential
firms in their respective sectors, including Xiaomi (SEHK:1810),
Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu
(NYSE: ZH, SEHK: 2390), Roborock (SHSE:688169), Gan & Lee
Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347),
Zai Lab (NASDAQ:ZLAB, SEHK:9688),
CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger
(NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health
(SEHK:6606), Venus MedTech (SEHK:2500), Sanyou Medical
(SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710),
SinocellTech (SHSE: 688520), Yuanxin Technology, dMed-Clinipace,
Belief BioMed, WeRide, Biren Technology and UBTech among many
SOURCE Qiming Venture Partners